We were interested in using SERPINA1 next generation sequencing (NGS) to assess whether additional sequence variants impact COPD presence and severity in a previously identified MZ cohort for AATD. This evidence concerns the gene SERPINA1 and alpha 1-antitrypsin deficiency.